Hans Matter

Hans Matter

Auto-generated profile, based on publicly available information

Hans Matter

R&D, Integrated Drug Discovery Sanofi‐Aventis Deutschland GmbH Frankfurt am Main Germany

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
THTobias Harren
Tobias Harren
HMHans Matter
Hans Matter
GHGerhard Hessler
Gerhard Hessler
MRMatthias Rarey
Matthias Rarey
CGChristoph Grebner
Christoph Grebner

27 December 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
LWLea Wenskowsky
Lea Wenskowsky
HSHerman Schreuder
Herman Schreuder
VDVolker Derdau
Volker Derdau
HMHans Matter
Hans Matter
JVJulia Volkmar
Julia Volkmar
SPStefan Matthias Petry
Stefan Matthias Petry

12 June 2023 in ACS Omega
Verified
Journal Article
Open access
MLMaxime Langevin
Maxime Langevin
CGChristoph Grebner
Christoph Grebner
SGStefan Güssregen
Stefan Güssregen
SSSusanne Sauer
Susanne Sauer
YLYi Li
Yi Li
MBMarc Bianciotto
Marc Bianciotto
Molecular generative artificial intelligence is drawing significant attention in the drug design community, with several experimentally validated proof of concepts already published. Nevertheless, generative models are known for sometimes generating unrealistic, unstable, unsynthesizable, or uninteresting structures. This calls for methods to constrain those algorithms to generate structures in drug-like portions of the chemical space. While the concept of applicability domains for predictive models is well studied, its counterpart for generative models is not yet well-defined. In this work, we empirically examine various possibilities and propose applicability domains suited for generative models. Using both public and internal data sets, we use generative methods to generate novel structures that are predicted to be actives by a corresponding quantitative structure–activity relationships model while constraining the generative model to stay within a given applicability domain. Our work looks at several applicability domain definitions, combining various criteria, such as structural similarity to the training set, similarity of physicochemical properties, unwanted substructures, and quantitative estimate of drug-likeness. We assess the structures generated from both qualitative and quantitative points of view and find that the applicability domain definitions have a strong influence on the drug-likeness of generated molecules. An extensive analysis of our results allows us to identify applicability domain definitions that are best suited for generating drug-like molecules with generative models. We anticipate that this work will help foster the adoption of generative models in an industrial context.

25 May 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HMHans Matter
Hans Matter
PKPeter Kotsonis
Peter Kotsonis
OKOtmar Klingler
Otmar Klingler
HSHartmut Strobel
Hartmut Strobel
LFLothar G. Fröhlich
Lothar G. Fröhlich
HSHarald H. H. W. Schmidt
Harald H. H. W. Schmidt

1 March 1994 in International Journal of Peptide and Protein Research
Verified
Journal Article
Closed access
PDF file
MGM. Gerz
M. Gerz
HMH. Matter
H. Matter
HKHorst Kessler
Horst Kessler

31 October 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
ARAnatoly M. Ruvinsky
Anatoly M. Ruvinsky
IAIshita Aloni
Ishita Aloni
DCDaniel Cappel
Daniel Cappel
CHChris Higgs
Chris Higgs
KMKyle Marshall
Kyle Marshall
HMHans Matter
Hans Matter